맘모그래피 시장 : 기술별, 도입 형태별, 제품 유형별, 용도별, 최종 사용자별 예측(2026-2032년)

The Mammography Market is projected to grow by USD 6.72 billion at a CAGR of 9.04% by 2032.

Mammography Market Introduction

Mammography remains the most widely deployed imaging modality for population-based breast cancer screening and diagnostic breast assessment. Its strategic importance is reinforced by the World Health Organization and the International Agency for Research on Cancer, which reported breast cancer as the world's most common cancer among women, with about 2.3 million new cases and approximately 670,000 deaths in 2022.

The mammography landscape is being shaped by full-field digital mammography, digital breast tomosynthesis, contrast-enhanced mammography, workflow software, and artificial intelligence-enabled image interpretation. Demand is supported by aging populations, national screening programs, dense breast notification requirements, and health-system priorities to detect breast cancer earlier, when treatment is typically more effective and less complex.

Transformative Shifts in the Mammography Landscape

The mammography landscape is shifting from analog and 2D digital workflows toward integrated breast imaging ecosystems. Digital breast tomosynthesis has expanded because it can reduce tissue overlap, improve lesion conspicuity, and support more confident reads, especially in women with dense breasts.

Regulation, clinical guidance, and reimbursement are also transforming adoption. In the United States, the FDA's updated Mammography Quality Standards Act rule requires facilities to provide breast density information in patient lay summaries, strengthening demand for risk-based screening pathways and supplemental imaging. In Europe, the European Commission Initiative on Breast Cancer emphasizes organized, quality-assured screening, while emerging markets are expanding access through public programs, mobile mammography units, and public-private partnerships.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across mammography acquisition, triage, interpretation, quality control, and reporting. FDA-cleared and CE-marked AI tools are increasingly used to flag suspicious findings, prioritize worklists, estimate breast density, and support radiologists facing high imaging volumes.

The strongest near-term value lies in workflow efficiency and consistency rather than full autonomy. Peer-reviewed studies show AI can support cancer detection and reduce false-positive workload when deployed with radiologist oversight, but clinical governance, bias monitoring, cybersecurity, data privacy, and local validation remain essential for safe implementation.

Key Regional Insights

North America is a mature mammography market, led by the United States and Canada, with high digital capacity, strong accreditation requirements, established breast cancer screening programs, and rising adoption of tomosynthesis and AI-enabled reading support. Dense breast notification and updated screening recommendations are reinforcing demand for personalized breast imaging pathways across hospital networks, outpatient imaging centers, and community screening providers.

Europe benefits from organized screening programs, cross-border quality standards, and broad public payer participation, although adoption speeds vary by country. Asia-Pacific is an expanding opportunity as China, India, Japan, South Korea, Australia, and ASEAN markets increase screening coverage, hospital investment, women's health awareness, and access to digital breast imaging. Latin America is advancing through mixed public-private systems in countries such as Brazil and Mexico, yet access remains uneven due to reimbursement constraints, workforce shortages, and urban-rural disparities. The Middle East is investing in premium diagnostic infrastructure and women's health initiatives, particularly in GCC health systems, while Africa continues to face access gaps linked to equipment availability, trained radiology workforce capacity, and screening program reach.

Key Group Insights

The European Union continues to influence mammography standards through organized screening, quality assurance, procurement frameworks, and policy alignment around cancer prevention and early diagnosis. G7 countries are generally early adopters of digital breast tomosynthesis, AI workflow tools, quality-assured screening, and risk-based breast imaging strategies, while NATO member markets overlap significantly with high-income screening systems that support modernization, cybersecurity, and interoperability across diagnostic networks.

BRICS countries are central to long-term mammography demand because of large populations, expanding hospital networks, rising breast cancer awareness, and growing investment in diagnostic imaging, though access, reimbursement, and screening coverage vary substantially. ASEAN markets are advancing through public screening campaigns, private diagnostic investment, mobile outreach, and urban hospital modernization, while GCC countries are investing in premium mammography infrastructure, women's health initiatives, digitally connected diagnostic services, and preventive care programs aligned with national health transformation agendas.

Key Country Insights

The United States is driven by Mammography Quality Standards Act compliance, high digital penetration, tomosynthesis adoption, breast density reporting, and AI-enabled workflow deployment. Canada emphasizes provincial screening programs, accreditation, and quality assurance, while Mexico and Brazil are expanding access through mixed public-private systems and broader cancer awareness initiatives. The United Kingdom, Germany, France, Italy, and Spain are shaped by organized screening, public health coverage, and modernization of breast imaging infrastructure; Russia maintains significant demand through large-scale public healthcare capacity and regional diagnostic networks.

China and India represent major mammography opportunity pools due to population size, hospital expansion, increasing cancer awareness, and rising investment in diagnostic imaging, although screening coverage and access remain uneven across provinces, states, and urban-rural settings. Japan, South Korea, and Australia have mature, quality-focused breast imaging pathways with strong technology adoption, established screening infrastructure, and emphasis on early detection. Across these countries, successful strategies depend on aligning product portfolios with local screening policy, reimbursement, radiologist capacity, accreditation requirements, patient access models, and breast density management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated mammography platforms that combine image quality, low-dose performance, tomosynthesis capability, breast density assessment, contrast-enhanced imaging readiness, and interoperable reporting. Vendors should invest in AI tools that integrate seamlessly into radiology workflows and demonstrate measurable improvements in reading efficiency, recall management, diagnostic confidence, and quality assurance.

Commercial strategies should be localized by screening policy, reimbursement, infrastructure readiness, and care-delivery model. Partnerships with hospitals, national screening programs, cancer centers, outpatient imaging networks, and mobile screening operators can expand access, while training programs for radiologists, technologists, and service teams can reduce implementation friction and strengthen long-term customer retention.

Research Methodology

This executive summary is built from secondary research across verified public-health, regulatory, clinical, and industry sources, including WHO, IARC, FDA, USPSTF, European Commission guidance, national screening program documentation, peer-reviewed radiology literature, and publicly available regulatory filings.

The analysis triangulates epidemiology, screening policy, technology adoption, reimbursement signals, installed-base modernization trends, and regional healthcare infrastructure. Insights are validated for consistency across multiple authoritative sources and framed to support strategic decision-making in mammography equipment, software, AI, services, and breast imaging operations without relying on market sizing or forecasting claims.

Conclusion

The mammography market is entering a more digital, data-driven, and patient-specific phase. Screening demand is supported by the global breast cancer burden, aging populations, dense breast reporting requirements, national screening programs, and health-system emphasis on earlier diagnosis.

Competitive advantage will increasingly depend on integrated platforms that combine tomosynthesis, AI-assisted interpretation, quality assurance, interoperability, cybersecurity, and service models that improve access. Organizations that align technology with clinical evidence, regulatory compliance, health equity priorities, and regional screening requirements will be best positioned for sustainable growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Mammography Market, by Technology

• 7.1. Analog Mammography
• 7.2. Digital Mammography
  • 7.2.1. 2D Imaging
  • 7.2.2. 3D Imaging

8. Mammography Market, by Deployment

• 8.1. Fixed
• 8.2. Portable

9. Mammography Market, by Product Type

• 9.1. Equipment
• 9.2. Services
  • 9.2.1. Maintenance
  • 9.2.2. Training
• 9.3. Software

10. Mammography Market, by Application

• 10.1. Diagnostic
  • 10.1.1. Biopsy Guidance
  • 10.1.2. Lesion Evaluation
• 10.2. Screening

11. Mammography Market, by End User

• 11.1. Clinics
  • 11.1.1. Breast Clinics
  • 11.1.2. Outpatient Clinics
• 11.2. Diagnostic Imaging Centers
  • 11.2.1. Multi Specialty
  • 11.2.2. Standalone
• 11.3. Hospitals
  • 11.3.1. Private
  • 11.3.2. Public

12. Mammography Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Mammography Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Mammography Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agfa-Gevaert Group
• 16.2. Allengers Medical Systems
• 16.3. Analogic Corporation
• 16.4. BMI Biomedical International s.r.l.
• 16.5. Canon Medical Systems Corporation
• 16.6. Carestream Health, Inc.
• 16.7. Digirad Corporation by TTG Imaging Solutions, LLC
• 16.8. Dilon Technologies, Inc.
• 16.9. Fujifilm Holdings Corporation
• 16.10. GE HealthCare Technologies Inc.
• 16.11. General Medical Merate S.p.A.
• 16.12. Genoray Co., Ltd.
• 16.13. Hologic, Inc.
• 16.14. iCAD, Inc. by RadNet, Inc.
• 16.15. IMS Giotto S.p.A
• 16.16. Konica Minolta, Inc.
• 16.17. Koninklijke Philips N.V.
• 16.18. Lunit Inc.
• 16.19. Metaltronica S.p.A.
• 16.20. Planmed Oy
• 16.21. Sectra AB
• 16.22. Shanghai United Imaging Healthcare Co., Ltd.
• 16.23. Shenzhen Anke High-tech Co., Ltd.
• 16.24. Siemens Healthineers AG
• 16.25. SternMed GmbH
• 16.26. Trivitron Healthcare
• 16.27. Varex Imaging Corporation